ArticleExploration of targeted anti-tumor therapy2023

Unexpected "Lazarus response" to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer.

Alexey V Emshanov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.